Paper · 42957722

RuPHOTACs provide photocontrol over protein degradation with optimized properties for biological applications.

Havrylyuk D and 5 others. Nat Commun, 2026.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. RuPHOTACs provide photocontrol over protein degradation with optimized properties for biological applications. Papers, record 42957722. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42957722

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: RuPHOTACs provide photocontrol over protein degradation with optimized properties for biological applications.
Journal: Nat Commun
Year: 2026
Publication types: Journal Article
PubMed: https://pubmed.ncbi.nlm.nih.gov/42957722/
DOI: https://doi.org/10.1038/s41467-026-78110-x
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC13720006/
The journal: https://conductscience.org/library/journal-index/101528555
Revised in PubMed: 2026-11-03

Source PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	ORCID iD
1	Havrylyuk D	Dmytro
2	LaMore AP	Ainsley P
3	Al-Hamaly MA	Majd A
4	Blackburn JS	Jessica S
5	Heidary DK	David K
6	Glazer EC	Edith C	https://orcid.org/0000-0002-0190-7742

Source PubMed

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Proteolysis	Major topic
Ruthenium	Major topic
Proteolysis Targeting Chimera
Humans
Ubiquitin-Protein Ligases
Animals
Light
Red Light

Source PubMed

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by
R01 GM162746	NIGMS NIH HHS	United States	R01GM162746	PubMed
R01GM162746	U.S. Department of Health & Human Services \| National Institutes of Health (NIH)		R01GM162746	PubMed

Source NIH RePORTER

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

Kind	PMID	Title	In Papers
Update of	41,727,614	RuPHOTACs Provide Photocontrol Over Protein Degradation with Optimized Properties for Biological Applications.	https://conductscience.org/library/papers/41727614

Source PubMed

References61

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	32,297,626	A caged E3 ligase ligand for PROTAC-mediated protein degradation with light.	Chem Commun (Camb)	2020	https://conductscience.org/library/papers/32297626	PubMed
2	34,508,258	The MYC oncogene - the grand orchestrator of cancer growth and immune evasion.	Nat Rev Clin Oncol	2022	https://conductscience.org/library/papers/34508258	PubMed
3	31,660,436	Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs.	ACS Cent Sci	2019	https://conductscience.org/library/papers/31660436	PubMed
4	39,055,140	Modular Development of Enzyme-Activatable Proteolysis Targeting Chimeras for Selective Protein Degradation and Cancer Targeting.	JACS Au	2024	https://conductscience.org/library/papers/39055140	PubMed
5	38,128,235	Development of visible-light-activatable photocaged PROTACs.	Eur J Med Chem	2024	https://conductscience.org/library/papers/38128235	PubMed
6	20,228,793	Potent and selective photo-inactivation of proteins with peptoid-ruthenium conjugates.	Nat Chem Biol	2010	https://conductscience.org/library/papers/20228793	PubMed
7	38,993,102	Conditional PROTAC: Recent Strategies for Modulating Targeted Protein Degradation.	ChemMedChem	2024	https://conductscience.org/library/papers/38993102	PubMed
8	34,788,776	Development of hypoxia-activated PROTAC exerting a more potent effect in tumor hypoxia than in normoxia.	Chem Commun (Camb)	2021	https://conductscience.org/library/papers/34788776	PubMed
9	36,323,630	A Versatile and Sustainable Multicomponent Platform for the Synthesis of Protein Degraders: Proof-of-Concept Application to BRD4-Degrading PROTACs.	J Med Chem	2022	https://conductscience.org/library/papers/36323630	PubMed
10	14,645,527	Ubiquitin depletion as a key mediator of toxicity by translational inhibitors.	Mol Cell Biol	2003	https://conductscience.org/library/papers/14645527	PubMed

1 to 10 of 61

See all 61 references

Cited by0

The papers in our copy of PubMed whose reference list names this one, newest first.

None in this release.

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42957722

GET https://conductscience.org/api/papers/v1/42957722/references?page=2

API reference For AI assistants